Mercury Bio Inc. has released promising results from a preclinical study that successfully utilized its extracellular vesicle (EV) drug encapsulation platform (yEV) to deliver proteins, in the form of nanobodies, into neurons across the blood-brain barrier. The yEV platform utilizes yeast-derived exosomes, a subtype of EV.